AbbVie and FutureGen announce license agreement to develop next-generation therapy for inflammatory bowel disease
AbbVie and FutureGen Biopharmaceutical have announced a license agreement to develop FG-M701, a next generation TL1A antibody for the treatment of IBD currently in preclinical development, whilst utilising FutureGen’s Structure-based Targeted...